Immunotherapy / PD-1 inhibitorFDA-approvedSecond-line
Nivolumab
How it works
Nivolumab is an antibody that blocks the PD-1 receptor on immune cells, allowing them to attack cancer cells.
Cancer types
Lung Cancer— All patients
Colorectal Cancer— All patients
Pancreatic Cancer— All patients
Ovarian Cancer— All patients
Leukemia— All patients
Efficacy
Studies show that nivolumab can improve overall survival in patients with pancreatic cancer, with a median overall survival of approximately 8.5 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Nivolumab Improves Survival in Lung Cancer Patients | Lung Cancer | phase-3 | Event-free survival seemed to be prolonged with nivolumab (hazard ratio, 0.48; 95% confidence interval, 0.28-0.83) in patients with single or co-alterations in any of the KEAP1, STK11, CDKN2A and/or SMARCA4 driver genes. | Source → |
| Nivolumab plus ipilimumab treatment shows promise for Japanese patients with lung cancer | Lung Cancer | phase-3 | Median overall survival was 41.0 months versus 15.2 months, with a 5-year overall survival rate of 38% versus 16%. | Source → |
| Testing a Special Diet with Immunotherapy in Melanoma Patients | Melanoma | phase-2 | — | Source → |
| Testing a Combination of Bexmarilimab and Nivolumab in Cancer | Lung Cancer | phase-1 | — | Source → |
| Testing a Combination of Vaccines and Immunotherapy for Advanced Lung and Head and Neck Cancers | Lung Cancer | phase-1 | — | Source → |
| Diabetes May Increase Side Effects of Cancer Treatment | Lung Cancer | observational | Nivolumab demonstrated similar antitumor activity in both groups, with no significant differences in median progression-free survival (PFS), overall survival (OS), or objective response rates. | Source → |
| Testing a New Vaccine and Medicine for Liver Cancer and Metastases | Colorectal Cancer | phase-2 | — | Source → |
| Combination Therapy Tested in Colorectal Cancer | Colorectal Cancer | phase-1/2 | The median progression-free survival was 1.7 months in patients with PIK3CA wild-type tumors and 1.6 months in patients with PIK3CA-mutant tumors. | Source → |
| Study Examines Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-2 | The confirmed PSA response rate was 21.6% in one group, and 20.5% in the other. | Source → |
| Testing a New Vaccine and Immunotherapy Combination for Colorectal and Pancreatic Cancer | Colorectal Cancer | phase-1 | — | Source → |
| Testing Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Immunotherapy for Localized Melanoma | Melanoma | phase-2 | — | Source → |
| Testing a New Combination Therapy for Advanced Colorectal Cancer | Colorectal Cancer | phase-1 | — | Source → |
| Rare Side Effect of Cancer Treatment Leads to Fatal Heart Attack | Melanoma | observational | — | Source → |
| Combining two cancer treatments may improve outcomes for some patients | Lung Cancer | phase-1/2 | Objective response rates were 18.2% for non-small-cell lung cancer, 18.5% for urothelial carcinoma, and 14.3% for hepatocellular carcinoma. | Source → |
| Immunotherapy Options for Colorectal Cancer | Colorectal Cancer | review | Pembrolizumab has a well-characterized long-term safety profile and superior progression-free and overall survival versus chemotherapy. | Source → |
| Combining Cancer Treatments Boosts Immune Response in Brain Metastases | Lung Cancer | lab-study | — | Source → |
| Evaluating Safety of Combination Therapy for Advanced Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Combining Radiotherapy and Immunotherapy for Lung Cancer | Lung Cancer | phase-2 | The objective response rate was 7% and 10% at 6 and 12 weeks, and reached 29% as the best response. | Source → |
| Testing Radiation Therapy with or without Nivolumab for Early or Recurring Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Focused Ultrasound to Open Blood-Brain Barrier for Lung Cancer Brain Metastases | Lung Cancer | phase-3 | — | Source → |
| New Prognostic Tool for Lung Cancer Patients on Nivolumab | Lung Cancer | observational | Patients with a CHAM score ≥ 4 had median survival times of 6.7 and 18.7 months, respectively. | Source → |
| Comparing Blinatumomab Alone to Blinatumomab with Nivolumab in B-Cell Acute Lymphoblastic Leukemia | Leukemia | phase-2 | — | Source → |
| Combining Immunotherapy and Radiation for Colorectal and Pancreatic Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Fecal Microbiota Transplant and Anti-PD-1 Therapy for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Testing Combination Therapy for Richter's Transformation | Leukemia | phase-2 | — | Source → |
| Comparing Nivolumab Administration at Home vs. in a Clinic | Colorectal Cancer | phase-2 | — | Source → |
| Testing a New Treatment Combination for Advanced Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Study of Nivolumab and Relatlimab in Untreated Melanoma | Melanoma | phase-3 | — | Source → |
| Melanoma Treatment Trial Investigates New Combination Therapy | Melanoma | phase-2 | — | Source → |
| Treating Advanced Melanoma with Combination Therapies | Melanoma | phase-3 | — | Source → |
| New Test for Lung Cancer Patients May Predict Treatment Response | Lung Cancer | lab-study | The area under the curve for miR-3613-5p improved from 0.837 to 0.897, and the hazard ratio increased from 3.386 to 7.815. | Source → |
| Genetic Factors May Influence Antibody Response to Cancer Treatment | Melanoma | lab-study | — | Source → |
| Testing Nivolumab and Ramucirumab for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Comparing Treatments for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing Nivolumab and Chemotherapy for Early Stage Lung Cancer in China | Lung Cancer | phase-2 | — | Source → |
| Taiwanese Study Examines Nivolumab and Chemotherapy for Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Testing Nivolumab and Radiation Therapy for Brain Metastases from Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Testing Combination Therapy for Melanoma Brain Metastases | Melanoma | phase-2 | — | Source → |
| Testing a Combination Treatment for Metastatic Melanoma | Melanoma | phase-2 | — | Source → |
| Testing Nivolumab and Ipilimumab for Advanced Squamous Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing Nivolumab and Relatlimab for Melanoma Brain Metastases | Melanoma | phase-2 | — | Source → |
| Study of Immunotherapy for High-Risk Melanoma | Melanoma | phase-2 | — | Source → |
| Testing a Combination Treatment for Pancreatic and Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing New Treatments for Relapsed or Refractory Leukemia | Leukemia | phase-1 | — | Source → |
| Testing Nivolumab and Hydroxychloroquine for Advanced Melanoma | Melanoma | phase-1 | — | Source → |
| Stopping Combo Immunotherapy for Melanoma Brain Metastases May Be Safe | Melanoma | observational | 4-year OS exceeded 83% in patients discontinuing COMBO after CR, PR, or toxicity following CR, compared with 66.4% in those discontinuing due to toxicity after PR. | Source → |
| Pancreatic Cancer Vaccine Trial Evaluates Personalized Treatment | Pancreatic Cancer | phase-1 | — | Source → |
| Evaluating Adaptive Dosing of Immunotherapy for Metastatic Melanoma | Melanoma | phase-2 | — | Source → |
| Combination Therapy for Untreated Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Testing a New Treatment for Advanced Melanoma | Melanoma | phase-1 | — | Source → |
| Testing Nivolumab for Leptomeningeal Disease | Lung Cancer | phase-1 | — | Source → |
| Testing Olanzapine with Nivolumab for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Comparing Chemotherapy and Chemo-Immunotherapy for Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing Immunotherapy with Chemotherapy for Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing New Treatments for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing a New Approach to Treating Advanced Melanoma | Melanoma | preclinical | — | Source → |
| Testing Immunotherapy in Advanced Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Testing Nivolumab in Rare Solid Tumors | Breast Cancer | phase-2 | — | Source → |
| Testing Combination Therapy for Advanced Skin Cancers in Kidney Transplant Recipients | Melanoma | phase-1 | — | Source → |
| Melanoma Patient Responds to Repeated Treatment with Ipilimumab and Nivolumab | Melanoma | observational | — | Source → |
| New Combination Therapy Tested in Early-Stage Lung Cancer | Lung Cancer | phase-1/2 | The 36-month recurrence-free survival was 80%. | Source → |
| Survival Outcomes After Stopping Nivolumab Due to Side Effects in Lung Cancer | Lung Cancer | observational | The median overall survival was 35.73 months (95% CI: 30.06-41.40). | Source → |
| Testing New Cancer Treatment in Combination with Existing Medications | Lung Cancer | phase-1 | — | Source → |
| Rare Sleep Disorder Linked to Cancer Treatment | Melanoma | observational | — | Source → |
| Rare Blood Disorder in Lung Cancer Patient Treated with Nivolumab | Lung Cancer | observational | — | Source → |
| Nivolumab and Ipilimumab Combination Shows Promise in Some Cancer Patients | Colorectal Cancer | phase-2 | The disease control rates for breast cancer and other solid tumors were 33% and 32%, respectively. | Source → |
| Testing Defactinib, Avutometinib, and Nivolumab for Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Comparing Ways to Give Melanoma Medications | Melanoma | phase-2 | — | Source → |
| Testing New Treatments for Advanced Melanoma | Melanoma | phase-2 | — | Source → |
| Testing IL2 and Immunotherapy in Advanced Melanoma Patients | Melanoma | phase-2 | — | Source → |
| Testing Nivolumab with Standard Treatment for Colorectal Cancer with BRAF Mutation | Colorectal Cancer | phase-2 | — | Source → |
| COVID-19 Vaccination May Improve Lung Cancer Treatment | Lung Cancer | observational | Patients receiving ≥2 mRNA doses had significantly longer PFS2 than those receiving 0-1 dose (14.0 vs. 9.6 months; p = 0.04). | Source → |
| Melanoma Treatment Trial Investigates Combination of NeoVax and Immunotherapies | Melanoma | phase-1 | — | Source → |
| Preventing Melanoma Recurrence with Nivolumab | Melanoma | phase-3 | — | Source → |
| Immunotherapy May Offer Better Survival for Lung Cancer Patients with Poor Health | Lung Cancer | phase-3 | Median overall survival was significantly longer with nivolumab: 29-weeks (95% CI: 11.3-46.7) versus 8-weeks (95% CI: 3.5-12.5; p<0.001) | Source → |
| Evaluating Nivolumab and Ipilimumab in Combination with Chemotherapy for Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Evaluating Nivolumab and Docetaxel for Advanced Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Testing Combination Therapy for Advanced Breast Cancer and Solid Tumors | Breast Cancer | phase-1 | — | Source → |
| Preventing Mucosal Melanoma Return After Surgery | Melanoma | phase-2 | — | Source → |
| Testing New Treatments for Advanced Melanoma That Has Progressed | Melanoma | phase-3 | — | Source → |
| Testing a New Combination Treatment for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Low-dose nivolumab shows promise in treating lung cancer | Lung Cancer | phase-2 | The estimated 2-year event-free survival rate was 56.1% (95% confidence interval [CI]: 38.3%-73.9%), and the 2-year disease-free survival rate was 66.6% (95% CI: 56.4%-86.8%). | Source → |
| Testing a New Treatment for Advanced Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Testing Nivolumab and Ipilimumab with Radiation in Advanced Rectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Testing Nivolumab to Prevent Leukemia Relapse | Leukemia | phase-2 | — | Source → |
| Testing Immunotherapy After Surgery for High-Risk Melanoma | Melanoma | phase-3 | — | Source → |
| Nivolumab and Ipilimumab Trial | Lung Cancer | phase-2 | — | Source → |
| Trial Tests Cancer Drugs in HIV Patients | Breast Cancer | phase-1 | — | Source → |
| Testing Tocilizumab with Immunotherapy for Advanced Melanoma | Melanoma | phase-2 | — | Source → |
| Immunotherapy Shows Promise for Rare Ovarian and Cervical Cancers | Leukemia | phase-2 | The overall response rate was 9.38%, with two complete responses that are ongoing at >3 years and one partial response. | Source → |
| Nivolumab's Safety and Effectiveness in Chinese Lung Cancer Patients | Lung Cancer | observational | The median overall survival was 21.2 months. | Source → |
| B cells and genetic changes may predict response to cancer treatment | Ovarian Cancer | phase-2 | More than two passenger fusion genes were detected in six of the seven responders, whereas eight of the ten non-responders lacked fusion genes. | Source → |
| GRIm Score Predicts Response to Melanoma Treatment | Melanoma | observational | Patients with a low GRIm Score had significantly longer median progression-free survival (21.4 vs. 6.3 months, p = 0.003) and overall survival (26.5 vs. 7.2 months, p < 0.001). | Source → |
| Combining Immunotherapy for Advanced Anal Cancer | Colorectal Cancer | phase-2 | The median progression-free survival was 2.9 months for nivolumab and 3.7 months for nivolumab plus ipilimumab. | Source → |
| Fatal Lung Disease after Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
| New Biomarker Predicts Outcomes for Lung Cancer Patients on Nivolumab | Lung Cancer | observational | Patients with GLR <70.76 achieved significantly longer OS (median 24.1 vs 9.6 months; p < 0.001) and PFS (9.7 vs 5.8 months; p < 0.001) compared with those with GLR ≥70.76. | Source → |
| Immunotherapy Response Predicted by Low Tumor Mutation Burden and PD-L1 Expression | Melanoma | observational | — | Source → |
| Long-term remission in lung cancer patient treated with nivolumab | Lung Cancer | observational | The patient remained in continuous remission with a progression-free survival exceeding 82 months and an overall survival exceeding 84 months. | Source → |
| Combining TM5614 and Nivolumab to Treat Advanced Melanoma | Melanoma | phase-3 | — | Source → |
| Rare Side Effect of Cancer Treatment in Older Patient | Melanoma | observational | — | Source → |
| Combination Therapy for Metastatic Melanoma Shows Promise in Real-World Study | Melanoma | observational | The response rate was 54% (39/72) and, after 13.6 months of median follow-up, a longer median progression-free survival [17.03 months (95% CI 4.8-18.6)]. | Source → |
| Blood Transfusions May Affect Lung Cancer Treatment Outcomes | Lung Cancer | observational | Median progression-free survival was 5.93 months, and median overall survival was 8.23 months. | Source → |
| Combination Cancer Therapy Linked to Kidney and Pancreas Damage | Lung Cancer | observational | — | Source → |
| Cost-Effectiveness of Lung Cancer Treatment Questioned | Lung Cancer | phase-3 | Nivolumab plus bevacizumab and chemotherapy yielded an additional 0.90 QALYs with the marginal cost of $231,948.33. | Source → |
| New Study Explores Using Nivolumab to Treat Malignant Ascites | Pancreatic Cancer | phase-2 | Seven patients (77.8%) showed a clinical response. | Source → |
| Melanoma Study Examines Vaccine Combination with Immunotherapy | Melanoma | phase-2 | Objective response rates were 59.7% and 59.2% in the two treatment arms. | Source → |
| Combining Nivolumab with Chemotherapy for Advanced Ovarian Cancer | Ovarian Cancer | phase-2 | Fifteen of the 20 evaluable patients had complete gross resection at ICS, and 7 of 20 achieved an optimal pathologic chemotherapy response score of 3. | Source → |
| Immune therapy may trigger severe colitis in some patients | Melanoma | observational | — | Source → |
| Combination Treatment Shows Promise for Rare Gynecological Cancers | Ovarian Cancer | phase-2 | The overall objective response rate was 54% (95% CI, 35-71), with 3 (12%) complete responses and 12 (42%) partial responses. | Source → |
| Study Examines Combination Therapy for Advanced Liver Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Cost-effectiveness of dual immunotherapy for lung cancer | Lung Cancer | phase-3 | Nivolumab plus ipilimumab provided an incremental gain of 1.11 and 0.96 QALYs over chemotherapy in the USA and China, respectively. | Source → |
| Comparing Two Ways to Give Cancer Treatment | Melanoma | phase-2 | — | Source → |
| Long-term Survival and Response to Immunotherapy in Melanoma Patients | Melanoma | phase-2 | At 4 years from the start of treatment, 80% of patients remained event-free, including 95% of patients who achieved a major pathologic response. | Source → |
| Combining RP1 and Nivolumab May Help Some Melanoma Patients | Melanoma | phase-2 | The confirmed objective response rate was 32.9% (95% CI, 25.2% to 41.3%; 15.0% complete response). | Source → |
| TIL Therapy for Melanoma Patients May Benefit from IFNα Support | Melanoma | phase-2 | Disease control was obtained in 11.1% of the patients treated without IFNα and in 41.7% of the patients treated with IFNα. | Source → |
| Rare Side Effect of Cancer Treatment: Tongue Discoloration | Ovarian Cancer | observational | — | Source → |
| Combination Therapy Improves Survival in Advanced Melanoma Patients | Melanoma | preclinical | The 4-year progression-free survival rate was 30.6% for nivolumab plus relatlimab versus 23.6% for nivolumab alone. | Source → |
| Combination Therapy Shows Promise for Metastatic Uveal Melanoma | Melanoma | observational | — | Source → |
| Nivolumab Fails to Improve Remission in Acute Myeloid Leukemia | Leukemia | phase-2 | The median progression-free survival was 13.2 months in the Nivo arm and 10.9 months in the Obs arm. | Source → |
| Color Vision Loss in Melanoma Patient Treated with Nivolumab-Relatlimab | Melanoma | observational | — | Source → |
| Nivolumab Treatment in Melanoma Patients: Immune and Nutritional Status Linked to Survival | Melanoma | observational | Patients with high HALP scores had significantly longer progression-free survival (PFS: median 5.8 vs 3.1 months) and overall survival (OS: median 54.9 vs 14.4 months) compared to those with low HALP scores. | Source → |
| Combining Telaglenastat and Nivolumab in Cancer Treatment | Melanoma | phase-1/2 | The overall response rate was 8.4% in the response-assessable analysis set. | Source → |
| Rare Side Effects of Cancer Treatment | Melanoma | observational | — | Source → |
| Nivolumab Effectiveness in Non-Small Cell Lung Cancer | Lung Cancer | observational | The 36-month OS rate was 19.7% (95% confidence interval [CI] 17.5-22.0); the 12-month investigator-assessed best ORR in the overall population was 20.4%. | Source → |
| Rare Side Effect of Cancer Treatment | Melanoma | observational | — | Source → |
| Inflammatory Markers and Metastases Predict Nivolumab Response in Lung Cancer | Lung Cancer | observational | The median overall survival was 21.2 months (95% CI: 17.4-25.0). | Source → |
| Brazilian Study Examines Cost of New Melanoma Treatments | Melanoma | observational | — | Source → |
| Researchers Test New Cancer Treatment in Rare Ovarian Cancers | Ovarian Cancer | phase-2 | The overall response rate was 25% in granulosa cell tumors, with 50% of patients experiencing clinical benefit. | Source → |
| Combination Therapy for Lung Cancer: A Meta-Analysis | Lung Cancer | meta-analysis | Non-small cell lung cancer patients who received combination therapy had better progression-free survival (HR = 0.82, 95% CI 0.71; 0.93, P < 0.01). | Source → |
| Relatlimab/Nivolumab Combination Therapy for Advanced Melanoma | Melanoma | review | — | Source → |
| Combining Entinostat and Nivolumab in Pancreatic Cancer | Pancreatic Cancer | phase-2 | The objective response rate was 11% (95% CI, 2.4%-29.2%) with a median response duration of 10.2 months. | Source → |
| Long-term Outcomes for Melanoma Patients Treated with Nivolumab and Ipilimumab | Melanoma | phase-3 | OS was longer with NIVO + IPI versus NIVO monotherapy (hazard ratio, 0.78 [95% CI, 0.67 to 0.91]), with 6-year OS rates of 52% versus 41%, respectively. | Source → |
| Melanoma patients' quality of life during immunotherapy treatment | Melanoma | observational | — | Source → |
| Melanoma Patients' Long-Term Survival Rates After Treatment | Melanoma | phase-3 | Estimated cure rates were 48.3% with nivolumab, 38.2% with ipilimumab, and 29.2% with placebo. | Source → |
| Long-term Outcomes with Nivolumab and Ipilimumab in Advanced Melanoma | Melanoma | phase-3 | Median overall survival was 71.9 months with nivolumab plus ipilimumab, 36.9 months with nivolumab, and 19.9 months with ipilimumab. | Source → |
| Study Compares Cancer Treatments for Rare Melanoma in Japanese Patients | Melanoma | observational | Objective response rates did not differ significantly between the NIVO+IPI and PD-1 groups (40.0% vs 27.7%). | Source → |
| Researchers Study Effectiveness of Cancer Treatment with Adaptive Dosing | Melanoma | phase-2 | The overall response rate was 47% (95% CI, 35%-59%) with a median follow-up of 34 months among survivors. | Source → |
| Melanoma Treatment Comparison Study Finds Similar Efficacy | Melanoma | phase-3 | Nivolumab plus relatlimab demonstrated similar progression-free survival (hazard ratio, 1.08 [95% CI, 0.88 to 1.33]) and overall survival (HR, 0.94 [95% CI, 0.75 to 1.19]) to nivolumab plus ipilimumab. | Source → |
| Combination Therapy Shows Promise in Lung Cancer Treatment | Lung Cancer | phase-2 | The estimated mean 6-month progression-free survival rate was 68.9% (high-MET group) and 50.9% (low-MET group). | Source → |
| Woman's Rare Brain Inflammation Linked to Cancer Treatment | Lung Cancer | observational | — | Source → |
| Nivolumab Monotherapy and Salvage Immunotherapy in Advanced Kidney Cancer | Melanoma | phase-2 | The 36-month mean time on protocol therapy was 11.5 months, and the 36-month mean TFS for the whole population was 9.4 months. | Source → |
| Nivolumab Shows Promise in Treating Rare Cancer | Lung Cancer | observational | The response rate was 8%, disease control rate was 37%, median progression-free survival was 5.7 months, and median overall survival was 11.1 months. | Source → |
| New Insights into Cancer Treatment for Children | Melanoma | phase-2 | — | Source → |
| Nivolumab treatment helps patient with advanced melanoma and liver failure | Melanoma | observational | — | Source → |
| Combining Vaccine and Immunotherapy in Early Prostate Cancer | Prostate Cancer | phase-2 | 21% of patients had a PSA decline >50%. | Source → |
| Nivolumab Not Cost-Effective for Relapsed Mesothelioma in China | Lung Cancer | phase-3 | Patients receiving nivolumab gained 0.65 quality-adjusted life-years (QALYs) compared to 0.43 QALYs for those receiving a placebo. | Source → |
| Combining Nivolumab and Chemotherapy in Lung Cancer Treatment | Lung Cancer | phase-3 | Median OS was 18.8 months with nivolumab plus chemotherapy versus 15.6 months with chemotherapy in patients with nonsquamous NSCLC. | Source → |
| Immunotherapy Shows Promise for Advanced Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| New Lung Cancer Treatment Combination Shows Mixed Results | Lung Cancer | phase-3 | The clinical benefit rate was 75.5% for sitra + nivo and 64.5% for docetaxel. | Source → |
| Combination Therapy Shows Promise for Advanced Melanoma | Melanoma | observational | — | Source → |
| Immune Checkpoint Inhibitors May Reduce Costs of Cancer Treatment | Lung Cancer | phase-3 | — | Source → |
| Combining Cancer Treatments May Help Some Patients with Advanced Melanoma | Melanoma | phase-2 | The combination of nivolumab and ipilimumab resulted in a statistically significant improvement in progression-free survival over ipilimumab (hazard ratio = 0.63). | Source → |
| Japanese Study Finds Safety of Nivolumab and Ipilimumab Combination Therapy for Melanoma | Melanoma | observational | — | Source → |
| Combining Immunotherapy Treatments Shows Promise in Pancreatic Cancer | Pancreatic Cancer | phase-2 | Treatment with GVAX+nivolumab+urelumab meets the primary endpoint by significantly increasing intratumoral CD8+ CD137+ cells (p = 0.003) compared to GVAX+Nivolumab. | Source → |
| Relatlimab-Nivolumab Combination for Metastatic Melanoma | Melanoma | review | — | Source → |
| Combining two drugs may help some patients with rare cancer complication | Leukemia | phase-2 | The overall response rate was 42%. | Source → |
| Combination Immunotherapy for Melanoma Brain Metastases | Melanoma | observational | Median overall survival was 5.45 months, with 21% of patients alive after 3 years. | Source → |
| Nivolumab Plus Relatlimab Shows Promise in Treating Advanced Melanoma | Melanoma | phase-2 | — | Source → |
| Melanoma Treatment Costs and Use Vary by Therapy Type | Melanoma | observational | — | Source → |
| Combining Nivolumab and Relatlimab to Treat Melanoma | Melanoma | phase-3 | Nivolumab and relatlimab produced more than a 2-fold median increase in progression-free survival (PFS) compared to nivolumab monotherapy. | Source → |
| Predicting Nivolumab Efficacy in Lung Cancer Patients | Lung Cancer | observational | The objective response and disease control rates at 25 weeks were 18.5 and 41.2%, respectively. | Source → |
| Combination Therapy Shows Promise in Treating Advanced Melanoma | Melanoma | phase-3 | The estimated 5-year RFS and OS rates for the neoadjuvant arm were 70% and 90% versus 60% and 70% for the adjuvant arm. | Source → |
| Sema4D silencing may improve melanoma treatment with nivolumab | Melanoma | lab-study | — | Source → |
| IMDC Risk Score Predicts Nivolumab Effectiveness in Renal Cancer and Melanoma | Melanoma | observational | — | Source → |
| Nivolumab Tested in Rare Cancer | Lung Cancer | phase-2 | — | Source → |
| Combining Immunotherapy for Melanoma Treatment | Melanoma | phase-2 | — | Source → |
| Nivolumab Levels Linked to Melanoma Treatment Outcomes | Melanoma | observational | — | Source → |
| Combination Immunotherapy Shows Promise in Treating Melanoma | Melanoma | phase-2 | The pathologic complete response rate was 57%. | Source → |
| New Treatment Option for Advanced Melanoma Patients | Melanoma | phase-1/2 | Nivolumab/relatlimab demonstrated a median progression-free survival (PFS) of 10.1 months. | Source → |
| Melanoma Treatment Comparison Study | Melanoma | phase-3 | The 2-year overall survival for those starting on arm A was 71.8% (95% CI, 62.5 to 79.1), and arm B 51.5% (95% CI, 41.7 to 60.4). | Source → |
| Combination Therapy Does Not Improve Survival in Melanoma Patients | Melanoma | phase-3 | 24-month RFS rates were 64.6% (combination) and 63.2% (nivolumab). | Source → |
| Combination Therapy Fails to Improve Lung Cancer Treatment | Lung Cancer | phase-2 | The objective response rate was 3.2%. | Source → |
| Side Effects of Cancer Treatment: A Rare Case of Colitis | Melanoma | observational | — | Source → |
| Rare Skin Reaction in Child with Cancer Treated with Nivolumab | Melanoma | observational | — | Source → |
| Real-world safety of nivolumab in melanoma patients | Melanoma | observational | — | Source → |
| Nivolumab Retreatment in Lung Cancer Patients | Lung Cancer | phase-2 | Nivolumab retreatment demonstrated an overall response rate of 8.5% and median progression-free survival of 2.6 months. | Source → |
| Long-term benefit of nivolumab plus low-dose ipilimumab in colorectal cancer | Colorectal Cancer | phase-2 | The investigator-assessed objective response rate increased from 55% to 65% at 50.9 months. | Source → |
| Rare Skin Cancer Linked to Melanoma Treatment | Melanoma | observational | — | Source → |
| Combining Immunotherapy and Radiation for Pancreatic Cancer | Pancreatic Cancer | phase-2 | The clinical benefit rate was 17.1% for patients receiving nivolumab and radiation, and 37.2% for patients receiving nivolumab and ipilimumab with radiation. | Source → |
| New Study Compares Melanoma Treatment with Two Immunotherapy Drugs | Melanoma | phase-3 | — | Source → |
| Neutrophils May Help Predict Melanoma Treatment Outcomes | Melanoma | lab-study | Patients with lower PD-L1 PMN frequencies displayed better progression-free survival (PFS) and overall survival (OS) compared to patients with high PD-L1 PMN frequencies. | Source → |
| Nivolumab Monotherapy for Advanced Lung Cancer in Asian Patients | Lung Cancer | phase-3 | Median overall survival was 14.7 months, and median progression-free survival was 3.6 months. | Source → |
| Nivolumab treatment in patients with kidney failure | Melanoma | observational | — | Source → |
| Long-term Outcomes of Melanoma Treatment with Nivolumab and Ipilimumab | Melanoma | phase-3 | Median overall survival was 72.1, 36.9, and 19.9 months in the combination, nivolumab, and ipilimumab groups, respectively. | Source → |
| Rare Side Effects of Cancer Treatment Cause Oral Ulcers and Adrenal Insufficiency | Lung Cancer | observational | — | Source → |
| Ipilimumab and Nivolumab Show Promise in Rare Aggressive Breast Cancer | Breast Cancer | phase-2 | The overall response rate was 18%. | Source → |
| Nivolumab Dose Escalation Triggers Rare Side Effect in Lung Cancer Patient | Lung Cancer | observational | — | Source → |
| Reusing Cancer Treatment May Not Work as Well Second Time Around | Melanoma | observational | The best overall response rate was 74% after the first course of ipilimumab/nivolumab, but only 23% after reinduction. | Source → |
| Rucaparib and Nivolumab Tested as Maintenance Treatment for Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
| Gastric Cancer Study Finds Tumor Mutation Burden and Indel Rate Linked to Treatment Outcomes | Leukemia | phase-2 | Patients with TMB ≥ 18.03/Mb and an indel rate of > 40% had a hazard ratio of 0.07 for progression-free survival and 0.09 for overall survival. | Source → |
| New Treatment Option for Advanced Lung Cancer | Lung Cancer | phase-3 | Overall survival was improved for patients who received nivolumab and ipilimumab, with a median OS of 18.1 months compared with 14.1 months for patients who received chemotherapy. | Source → |
| Nivolumab Safety in Stage III/IV Melanoma Patients | Melanoma | phase-3 | — | Source → |
| Rare Mediastinal Melanoma Shrinks with Immunotherapy | Melanoma | phase-2 | nivolumab monotherapy caused remarkable tumor shrinkage | Source → |
| New Tool Helps Doctors Decide Next Steps for Lung Cancer Patients | Lung Cancer | lab-study | — | Source → |
| Rare Skin Reaction Linked to Cancer Treatment | Melanoma | observational | — | Source → |
| Nivolumab treatment for HIV-infected lung cancer patients | Lung Cancer | phase-2 | The disease control rate was 62.5% for 15 evaluable patients at 8 weeks. | Source → |
| Rare Esophageal Cancer Treated with Nivolumab | Melanoma | observational | — | Source → |
| Weight Loss Linked to Poor Prognosis in Lung Cancer Patients | Lung Cancer | observational | Loss of body weight of >2% at week 6 was an independent predictor for poor OS (hazard ratio 2.39, 95% confidence interval 1.51-3.79, P < 0.001) | Source → |
| Rare Lymphoma Linked to Cancer Treatment | Lung Cancer | observational | — | Source → |
| Lung Cancer Study Finds New Way to Predict Treatment Success | Lung Cancer | observational | Median progression-free survival for subjects with NLR <3 before treatment was 18.5 weeks, while in subjects with NLR ≥3 was 14 weeks. | Source → |
| Nivolumab Fails to Improve Survival in Relapsed Small-Cell Lung Cancer | Lung Cancer | phase-3 | Median progression-free survival was 1.4 versus 3.8 months (HR, 1.41; 95% CI, 1.18-1.69). | Source → |
| Rare Side Effects of Cancer Treatment | Melanoma | observational | — | Source → |
| Cost-effectiveness of nivolumab in treating small cell lung cancer | Lung Cancer | phase-3 | Mean overall survival was 21.69 months with nivolumab and 5.80 months with IV or oral topotecan. | Source → |
| Large Spleen May Predict Poor Outcomes in Pancreatic Cancer Treatment | Pancreatic Cancer | observational | Among 31 evaluable patients, the response and disease control rates were 7% and 36%, respectively. | Source → |
| Gene Expression May Predict Response to Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Testing for Cancer Gene May Improve Effectiveness of Lung Cancer Treatment in China | Lung Cancer | phase-3 | The PD-L1 test-based strategy yielded an additional 0.27 QALYs compared to the docetaxel strategy without a PD-L1 test. | Source → |
| Combining Cancer Drugs with Anti-Inflammatory Medications in Melanoma Patients | Melanoma | preclinical | Seven of seven evaluable patients achieved objective response, including four complete responses and three partial responses, in the certolizumab cohort. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.